Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents

2018907 citationsJournal Articlebronze Open Access

Authors

Frederick G. Hayden · University of Virginia

Norio Sugaya · keiyu Hospital

Nobuo Hirotsu

Nelson Lee · University of Alberta

Menno D. de Jong · University of Amsterdam

Aeron C. Hurt · University of Melbourne

Tadashi Ishida · Kurashiki Central Hospital

Abstract

Single-dose baloxavir was without evident safety concerns, was superior to placebo in alleviating influenza symptoms, and was superior to both oseltamivir and placebo in reducing the viral load 1 day after initiation of the trial regimen in patients with uncomplicated influenza. Evidence for the development of decreased susceptibility to baloxavir after treatment was also observed. (Funded by Shionogi; JapicCTI number, 153090, and CAPSTONE-1 ClinicalTrials.gov number, NCT02954354 .).

Topics & Keywords

Influenza Virus Research Studies Respiratory viral infections research Viral Infections and Immunology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 379, Issue 10, pp. 913-923

DOI: 10.1056/nejmoa1716197

Field-Weighted Citation Impact: 72.05